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IMPORTANCE Bonymetastatic castrate-refractory prostate cancer (CRPC) has a poor
prognosis and highmorbidity. Zoledronic acid (ZA) is commonly combined with docetaxel in
practice but lacks evidence that combining is effective, and strontium-89 (Sr89) is generally
used palliatively in patients unfit for chemotherapy. Phase 2 analysis of the TRAPEZE trial
confirmed combining the agents was safe and feasible, and the objectives of phase 3 include
assessment of the treatments on survival.
OBJECTIVE To determine clinical effectiveness and cost-effectiveness of combining
docetaxel, ZA, and Sr89, all having palliative benefits and used in bonymetastatic CRPC to
control bone symptoms and, for docetaxel, to prolong survival.
DESIGN, SETTING, ANDPARTICIPANTS TheTRAPEZE trial is a 2 × 2 factorial trial comparing
docetaxel alone orwith ZA, Sr89, or both. A cohort of 757 participantswere recruited between
February 2005andFebruary 2012 fromhospitals in theUnitedKingdom.Overall, 169
participants (45%)had receivedpalliative radiotherapy, and themedian (IQR) prostate-specific
antigen levelwas 146 (51-354). Follow-upswere performed for at least 12months.
INTERVENTIONS Up to 10 cycles of docetaxel alone; docetaxel with ZA; docetaxel with a
single Sr89 dose after 6 cycles; or docetaxel with both ZA and Sr89.
MAIN OUTCOMES ANDMEASURES Primary outcomes included clinical progression-free
survival (CPFS) (pain progression, skeletal-related events [SREs], or death) and
cost-effectiveness. Secondary outcomes included SRE-free interval, pain progression–free
interval, total SREs, and overall survival (OS).
RESULTS Overall, of 757 participants, 349 (46%) completed docetaxel treatment. Median
(IQR) age was 68 (63-73) years. Clinical progression-free survival did not reach statistical
significance for either Sr89 or ZA. Cox regression analysis adjusted for all stratification
variables showed benefit of Sr89 on CPFS (hazard ratio [HR], 0.85; 95% CI, 0.73-0.99;
P = .03) and confirmed no effect of ZA (HR, 0.98; 95% CI, 0.85-1.14; P = .81); ZA had a
significant effect on SRE-free interval (HR, 0.78; 95% CI, 0.65-0.95; P = .01). For OS, there
was no effect of either Sr89 (HR, 0.92; 95% CI, 0.79-1.08; P = 0.34) or ZA (HR, 0.99; 95% CI,
0.84-1.16; P = 0.91).
CONCLUSIONS AND RELEVANCE Strontium-89 combinedwith docetaxel improved CPFS but
did not improve OS, SRE-free interval, or total SREs; ZA did not improve CPFS or OS but did
significantly improvemedian SRE-free interval and reduced total SREs by around one-third,
suggesting a role as postchemotherapymaintenance therapy.
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P rostate cancer is amajorhealthproblemworldwideandaccounts fornearlyone-fifthofallnewlydiagnosedmalecancers. In theUnitedKingdom, approximately 35000
menarediagnosedwithprostate cancereachyear, and in2008
almost 10000men died from the disease.1
Hormone therapy has been themainstay of treatment for
relapsedprostate cancer since the seminal studies ofHuggins
and Hodges.2 Responses to primary hormone therapy typi-
cally last 12 to 24monthsdependingondisease stage. This pe-
riodafter failureof initial androgen-deprivation therapy isnow
termedcastrate-refractoryprostatecancer (CRPC)with the rec-
ognition that relapsing tumors remain dependent on andro-
gen receptor-mediated pathways reflected in the licensing of
abiraterone3andenzalutamide.4Chemotherapywithdocetaxel
is also a mainstay of therapy for metastatic CRPC following 2
landmark trials published in 2004.5,6 Second line chemo-
therapy with cabazitaxel was licensed in 2010.7
InpatientswithmetastaticCRPC,bonesareoneof themost
commonsitesof spread,amajorcauseofmorbidity inmenwith
CRPC. A number of treatments are approved for bone disease,
including zoledronic acid (ZA),8,9 denosumab,10 strontium-89
(Sr89),11,12 samarium-153 and, more recently, radium-223.13 A
predocetaxel era trial combined chemotherapy with Sr89 in a
small randomizedtrialandsuggestedasurvivaladvantageinpa-
tientsallocatedtoSr89.14Zoledronicacidanddenosumabareap-
provedonthebasisofreductionsinskeletal-relatedevents(SREs),
acompositeendpoint.Skeletal-relatedevents includeanyofthe
following: symptomaticpathologicalbone fracture; spinal cord
ornerve root compression likely tobe related tocanceror treat-
ment; cancer-relatedsurgery tobone; radiationtherapytobone
(includinguseofradioisotopes);changeofantineoplastictherapy
to treatbonepaindue toprostate cancer; orhypercalcemia.For
this studyweonlycollectedclinicallyapparentSREs, and there
wasnoattempt to identify subclinical SREsby repeat radiologi-
calexamination.Thetrial recruitedbetweenFebruary2005and
February 2012, prior to the prechemotherapy licenses for abi-
raterone and enzalutamide. Hence, no patients received life-
prolongingtherapyforCRPCpriortodocetaxel.Patientsrecruited
inthelaterstagesofthetrialwouldhavebeenabletoreceivethese
therapies postchemotherapy.
The TRAPEZE study sought to assess whether the addi-
tion of either Sr89, ZA, or both could offer a significant addi-
tional benefit in men receiving standard docetaxel and pred-
nisolone in CRPC metastatic to bone. Prior therapy with
bisphosphonates was permitted but should have stopped 2
months prior to study entry.
Methods
Trial Design and Participants
TRAPEZEwasarandomized,open-label,phase3trialusinga2 × 2
factorial design (eFigure 1 in Supplement 1). The trial was de-
signed toevaluatewhether additionalbone targeting therapies
improvedclinicalandhealtheconomicoutcomescomparedwith
chemotherapy alone. The trial included an initial randomized
phase 2 element to assess feasibility, tolerability, and safety of
theexperimentalarms.Phase3proceededseamlesslyfromphase
2,andtheobjectivesweretoassesstreatmentswithina2 × 2fac-
torialdesignframework(ie,thetrialcomparedZAvsnoZA[strati-
fied for Sr89 use] and Sr89 vs no Sr89 [stratified for ZA use]).
Phase 3 had dual primary outcomes of the treatment effect on
time to clinical progression-free survival (CPFS) and cost-
effectiveness. Trial protocol can be found in Supplement 2. In
this article,we reporton treatmenteffecton timetoCPFS; cost-
effectivenesswill be reported elsewhere.
We recruited patients older than 18 yearswith progressive
metastaticCRPC,with1ormorescleroticbonemetastases.Con-
sentingparticipants had anECOG (EasternCooperativeOncol-
ogyGroupscore)of0to2andadequatehematological, renal,and
hepatic function.Principalexclusionswerepriorchemotherapy
orradionuclidetherapyforCRPC,priorradiotherapytomorethan
25%ofbonemarrow,bisphosphonate therapywithin2months
oftrialentry,othermalignantdiseasewithintheprevious5years,
knownbrainmetastases, symptomaticperipheralneuropathy,
andparticipation inanyotherclinical trialwithin30daysof trial
entry.Thetrial receivedethicalapprovalfromtheUKMulticenter
ResearchEthicsCommitteeandregulatoryapproval fromtheUK
MedicinesandHealthcareRegulatoryAgencyinNovember2004.
Inaddition,eachparticipatingcenterobtainedlocal institutional
review board approval.Written consent was obtained from all
study participants.
Interventions
Patientswere randomized to 1 of 4 arms. Participants inArmA
received3 intravenousdosesof75mg/m2docetaxelperweekup
to 10 cycles;ArmB, 3 intravenousdoses of 4mgdocetaxel plus
zoledronic acid (DZA) per week during chemotherapy then 4
doses per week until disease progression; Arm C, 6 cycles of
docetaxel (75mg/m2every21days) followedbya150MBqsingle
dose of Sr89 (DSr89) then4 further cycles of docetaxel; ArmD,
docetaxel plus doses of both Sr89 and ZA (DSZ) previously de-
scribed (eFigure 2 in Supplement 1). Inphase2, docetaxel in all
armswas administered for 6 cycles with 4 further cycles at in-
vestigatordiscretion,but theprotocolwas later altered tobring
all 10cyclesof chemotherapywithin theprimary treatmentpe-
riod. Patientswere stratified by investigation center andECOG
performancestatusat trial entry ina1:1:1:1 allocationratiousing
Key Points
QuestionWhat is the clinical effectiveness of docetaxel alone or
with strontium-89, zoledronic acid, or both in patients with bony
metastatic castrate-refractory prostate cancer?
Findings Strontium-89 combined with docetaxel improved clinical
progression-free survival but did not improve overall survival,
skeletal-related event–free interval, or total skeletal-related
events. Zoledronic acid did not improve clinical progression-free
survival or overall survival but did significantly improvemedian
skeletal-related event–free interval and reduced total
skeletal-related events by around one-third.
Meaning Strontium-89 showedmodest benefits but probably has
now been superseded, and zoledronic acid should be considered
a component of therapy for men with progressive bony
castrate-refractory prostate cancer.
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acomputerizedminimizationalgorithmaccessedby telephone
to the trials unit.
Outcome Assessment
The primary phase 3 analysis compared ZA vs no ZA (strati-
fied for Sr89 use) and Sr89 vs no Sr89 (stratified for ZAuse) in
terms of CPFS defined as the number of whole days from the
date of randomization to the first occurrence of a sympto-
matic SRE, painprogression, or death. Patients not experienc-
ing clinical progression were censored at the date last known
to be progression free. Secondary outcome measures were
symptomatic SRE-free interval, pain progression–free inter-
val, overall survival (OS), andnumbers of SREs.A SRE-free in-
terval was defined as the time in whole days from the date of
randomization to the date of the first occurrence of a SRE. Pa-
tients who did not experience a SRE were censored at death
or the date last known to be alive. There was no protocol-
mandated radiological assessment; all SREswere clinicallyde-
tected.Apainprogression–free intervalwasdefinedas the time
in whole days from the date of randomization to the date of
clinician-determinedpainprogression.Overall survivalwasde-
fined as the number of whole days from the date of random-
ization to the date of death from any cause. Additional data
were collected on the number and type of SREs reported.
Statistical Analysis
Sample size calculationswere based on the primary outcome
measure of CPFS. The calculationswere the same for both the
comparisonofZAvsnoZAandSr89vsnoSr89.The trial aimed
to detect a hazard ratio (HR) of 0.76, which would be the
equivalent to 1 yearCPFS rates of 30%vs40%, assumingCPFS
followed an exponential distribution. The number of events
required todetect thisdifference ineachgroup for either treat-
ment comparison, using a 2-sided 5% significance level and
80%power,was206. Itwasestimated that approximately294
participants would be required in each group (ie, 588 pa-
tients in total) to observe this number of events at a 1 year fol-
low-up. We aimed to recruit a minimum of 618 evaluable pa-
tients, which allowed for 5% dropout. Final recruitment was
inflated by 20% to enable a per protocol analysis to be con-
ducted including only those patients who remained fit to re-
ceive Sr89 following 6 cycles of docetaxel.
Factorial 2 × 2designs assumeno interactionbetween the
2 agents, and this assumption was investigated both graphi-
cally andby inclusionof interaction termswithinaCoxmodel.
Thefirstanalysisof theprimaryoutcomewasanunadjusted
stratified log-ranktestonwhichthesamplesizewasbasedcom-
paringZAvsnoZAstratifiedbySr89useandcomparingSr89vs
noSr89stratifiedbyZAuse.Thesecondanalysisof theprimary
outcomeusedanadjustedCoxregressionmodel, includingboth
treatment comparisons and stratification factors (ie, ECOGand
randomizingcenter).Theuseof stratification factorswithin the
design leadstocorrelationbetweenthetreatmentgroups.These
correlations,whennotadjustedfor,canleadto inflatedstandard
error rates for treatmenteffects, confidence interval thatare too
wide,P values that are too high, and a subsequent reduction in
power.15Owingtothesepotential implications,ourprimaryout-
come conclusions have beenbasedon the adjustedCox regres-
sionanalysis.Theuseofboth log-rankandCoxregressionmod-
elswasprespecifiedinthetrialprotocol.GraphsusingtheKaplan-
Meiermethod are presented.
SecondaryoutcomemeasuresofOS,painprogression free–
interval, and SRE-free interval were all analyzed using the
stratified log-rankmethodologywithHRs and confidence in-
tervals (CIs) taken from an associated Cox regression.
Results
Study Participants
Atotalof1031patientswereassessedforstudyentry,and757con-
sented to enter the trial between February 2005 and February
2012andare included inthe intention-to-treatanalysis summa-
rized in theCONSORTdiagram(eFigure3 inSupplement 1).Me-
dian (interquartile range[IQR])agewas68(63-73)yearsat study
entry, andmedian (IQR)prostate-specific antigen levelwas 144
(51-354). Patientswereevenlydistributedacross thearmswith
respect toECOGperformancestatus,prior radiotherapy,painat
studyentry, analgesic scores,numberofmetastatic sitesand lo-
cation ofmetastases (Table 1).
Treatment
Of 757 participants, 349 (46%) completed docetaxel treat-
ment. There were 3 main reasons participants did not com-
plete docetaxel treatment: 118 participants (29%) haddisease
progression; 49 participants (12%) suffered intolerable toxic
effects; and 122 participants (30%) developed another condi-
tion or occurrence that in the opinion of the treating clinician
justifieddiscontinuationofdocetaxel.Of theparticipants ran-
domized to receive Sr89, 253 (67%) of the patients random-
ized to receive Sr89 did so. The remainder did not complete
therapymainlyowing to early cessationof chemotherapy.Ad-
ditional details on therapy discontinuation can be seen in the
CONSORT diagram (eFigure 3 in Supplement 1). Chemo-
therapy delivery rates were similar across all arms.
For those who received 10 cycles of docetaxel, the addi-
tionof Sr89didnot affectdocetaxel doses given. In total, there
were267docetaxel reductionsaffecting6%ofcyclesgivenwith
no significant differences between arms. In all arms, the pre-
dominant reason for dose reductionwerehematological toxic
effects related to trial treatments. In total, 297 (7%) docetaxel
treatment cycles were delayed with no significant differ-
ences between arms. Overall, 86 delays (29%) were owing to
administrative reasonsor patient choice.Of the remainingde-
lays, 89 (30%) were owing to toxic effects, and there were 62
delays (21%) in thedocetaxel alone arm,95 (32%) in theDSr89
arm, and 107 36% in the 2 remaining arms.
Patients were able to receive additional life-prolonging
treatments following clinical progression, although therewas
limited availability until 6 years into the trial (the final year of
randomization). Of the participants who received additional
life-prolonging treatments, 124 (17%) reported receiving abi-
raterone; 2 (0.3%), radium223; 40 (4%), cabazitaxel; 62 (9%),
rechallenged with docetaxel; 3 (0.5%), enzalutamide; and
1 (0.1%), samarium 153. In addition, 36 participants (5%) re-
ceived Sr89 off-study and 136 (18%) received ZA off-study.
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Toxic Effects
Overall, 493knowngrade3or4adverseevents16were reported
relatingto237patientsandwereequallydistributedbetweenthe
treatmentarms.Thetop5(accountingfor42%ofgrade3to4ad-
verseevents)werepain,fatigue,hemoglobinchanges,febrileneu-
tropenia, andneutrophil changes.Eighteen instancesof fatigue
eventswerereportedintheDSr89armvs10fatigueevents inthe
DZSarm,9 in theDZAarm,and9 inthedocetaxelarm.Fourteen
instances of febrile neutropeniawere reported in thedocetaxel
arm comparedwith 8 instances in the DZA arm, 8 in the DSr89
arm,and6 in theDSZarm.Therewere5Hemoglobinchanges in
the docetaxel arm vs 14 in the DSZ arm, 12 in the DZA arm, and
11 intheDSr89arm,andtherewereonly9instancesofpaininthe
DZA armvs 16 in theDSr89 arm, 13 in the docetaxel arm, and 11
intheDSZarm.Intotal,583seriousadverseeventswerereported,
relatingto373(49%)patients.Ofthese286(49%)wereunrelated
seriousadverseeventsand276(47%)wereseriousadversereac-
tions.The remainingwere21 suspectedunexpectedseriousad-
versereactions,4 inthedocetaxelarm,3 intheDZAarm,6 inthe
DSr89 arm, and8 in theDSZ arm.
Clinical Progression-Free Survival
At the timeof analysis, survivingpatientswere followedup for
amedianof22months. In total, therewere696clinicalprogres-
sionevents reported.Noevidenceof interactionbetweenSr89
and ZAwas found (P = .40), validating the factorial design. As
showninFigure1A, theadditionofZAhadnosignificant impact
onCPFS.This isconfirmedbyboththeunadjustedstratified log-
rank test (P = .76)andtheadjustedCoxregressionanalysis (HR,
0.98;95%CI,0.85-1.14;P = .81). Figure 1B shows theoutcomes
forSr89,andtheunadjustedstratifiedlog-ranktestdidnotreach
statistical significance (P = .12). However, the adjusted Cox re-
gressionanalysisshowedevidenceofamoderateeffect(HR,0.85;
95%CI, 0.73-0.99; P = .03).
OS and Pain Progression Free Interval
Stratified log-rank tests for secondary outcomes found no sta-
tisticallysignificantdifferences inpainprogressionfree interval
(ZA:HR,0.91;95%CI,0.75-1.10;P = .31andSr89:HR,0.92;95%
CI,0.76-1.11;P = .40)orOS.MedianOSwithandwithout either
agentwasnotsignificantlydifferent: 16.99and17.06months for
ZA (HR, 0.99; 95% CI, 0.84-1.16; P = .91) and 18.17 and 16.59
months for Sr89 (HR, 0.92; 95%CI, 0.79-1.08; P = .34).
SRE-Free Interval
In total, 437 patients experienced at least one SRE. Figure 2A
showstheeffectofZA,whichprolongedthemedianSRE-free in-
terval from11.2 to13.6months (HR,0.78;95%CI,0.65-0.95;P =
.01).Surprisingly,Sr89didnotsignificantlyprolongtheSRE-free
interval (HR,0.88;95%CI,0.73-1.06;P=.17), thoughthemedian
SRE-free intervaldid increase from11.7 to13.0months, suggest-
ing aweakeffect (Figure 2B). Prespecified subgroupanalysis of
531patients(70%)whowerefit toreceiveSr89followingcomple-
tion of 6 cycles of docetaxel showed that 321 SREs occurred in
total.Strontium-89didnotsignificantlyprolongperprotocol the
SRE-free interval (HR,0.85;95%CI,0.68-1.05;P = 0.13), though
themedianSRE-freeinterval increasedfrom12.75to14.16month
with the addition of Sr89.
At the time of analysis, 557 participants (82%) were de-
ceased, meaning their SRE data are complete. Surviving
Table 1. Patient Baseline Characteristics
Characteristic
ZA Sr89
No ZA ZA No Sr89 Sr89
Age, y, median (IQR) 68 (63-73) 69 (64-73) 68 (64-73) 68 (63-73)
PSA, median (IQR) 147 (51-347) 143 (51-374) 144 (54-354) 147 (48-349)
ECOG, No. (%)
0 153 (40) 152 (40) 153 (40) 152 (40)
1 195 (51) 194 (51) 195 (52) 194 (51)
2 33 (9) 30 (9) 31 (8) 32 (9)
Prior radiotherapy, No. (%) 169 (45) 168 (45) 157 (42) 180 (48)
Daily Present Pain Index (scale 0-5), median (IQR) 1.4 (1-2) 1.5 (0.7-2) 1.6 (0.9-2) 1.4 (0.7-2)
Daily analgesic score, median (IQR) 10 (1-28) 10 (1-28) 11 (1-29) 9 (1-24)
Site of metastatic disease in addition to bone,
No. (%)
Liver 26 (7) 34 (9) 26 (7) 34 (9)
Lymph 167 (44) 159 (42) 145 (38) 181 (48)
Lung 41 (11) 38 (10) 38 (10) 41 (11)
Other soft tissue 9 (2) 17 (5) 13 (3) 13 (3)
Other 33 (7) 22 (6) 29 (8) 26 (7)
Metastatic sites, No. (%)
1 204 (54) 216 (57) 218 (58) 202 (53)
2 111 (29) 92 (24) 97 (26) 106 (28)
3 37 (10) 34 (9) 36 (9) 35 (9)
4 6 (2) 13 (3) 7 (2) 12 (3)
5 2 (0.5) 2 (0.5) 2 (0.5) 2 (0.5)
Abbreviations: ECOG, Eastern
Cooperative Oncology Group score;
IQR, interquartile range;
PSA, prostate-specific antigen;
Sr89, strontium-89;
ZA, zoledronic acid.
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patients were equally distributed between arms. Total SREs at
the time of analysis (Table 2) showed no effect owing to Sr89
(494vs535), but therewas adecreaseof 30% inoverall SREs in
participants allocated to ZA therapy (424 vs 605). In addition,
the number of participants experiencing 2 ormore SREs in ZA
arms decreased from 154 (40%) to 103 (27%) and participants
experiencing no SREs increased from 147 (39%) to 173 (46%)
(eTable inSupplement1).WhenthedistributionofSREswasex-
amined, the proportionate effect of ZA was greatest on those
experiencing themost severeevents,namelypathological frac-
ture, surgery to bone, hypercalcemia, or spinal cord compres-
sion.Therewere62 (54%) fewer instancesof severeSREs inpa-
tientswhoreceivedZA,withanoverall reductionof94instances
(24%) in the use of radiotherapy for bone pain.
Discussion
Therewere2keystrands to theevaluationof the trial: theclini-
cal effectiveness of the 2 treatments and the health
economic aspects that will be covered in a separate paper. As
therewasno interactionbetweentheeffectsof the2therapies—
Sr89andZA—theeffectswereconsideredseparately.Therecent
AdvancedProstateCancerConsensusConference (APCCC)17 in
StGallenstrongly supported theuseof chemotherapy inCRPC,
but no consensus on timingwas reached.17 For bone targeting
therapies, there was no consensus on whether to use these
agents in some,all, ornopatientswithbonedisease.Therewas
alsono consensusbetweenuseof ZAordenosumab.By focus-
ing on symptomatic skeletal events, our article broadens our
knowledge about the clinical value of ZA in the docetaxel era.
Strontium-89
TheadditionofSr89 tochemotherapyhada favorableeffecton
the timetobonyclinicaldiseaseprogressionbutnoeffectonOS
was observed. Given the previous data on Sr89,11 therewas no
effectonSREs intermsoftimetofirstSRE, totalnumberofSREs,
or distribution.Despite the positive primary outcome, it is less
clearwhetherour findingswill alter theuseofSr89significantly
for anumberof reasons.First, thegain inCPFS (aboutamonth)
is likely to be seen asmodest. Additionally, therewas no effect
on the frequency that subsequent SREs were observed. At the
timeof study inception, this, coupledwithamodestquality-of-
life gain, may have been adequate to change clinical practice.
Figure 1. Clinical Progression-Free Survival
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Figure 2. Skeletal-Related Event-Free Interval
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However,wehaveseenanumberofnewtreatments licensed in
the last few years that improve overall survival postchemo-
therapy,aswellas improvequalityof lifeandSREs.Theseinclude
abiraterone,3 enzalutamide,4 cabazitaxel7 and,ofparticular rel-
evancetothisstudy, radium-223.13Radium-223,beingacalcium
mimeticagent, isaradioisotopewithasimilaruptakemechanism
toSr89.However, αemissionsof radium-223deliver amore in-
tenseand localized radiationdose than theβemissionsofSr89.
ThekeyALSYMPCAtrialof radium-22313showedimprovements
in bothOS and symptomatic SREs.
Zoledronic Acid
The addition of ZA to docetaxel did not affect OS or CPFS
postchemotherapy.Therewas,however, a substantial effecton
symptomaticSREs.DefiningSREs is controversialbecause they
areacompositeendpoint. InboththeZAanddenosumablicens-
ingtrials,18akeycomponent(pathological fracture)wasassessed
byblindedexaminationofserialradiographsratherthanwithref-
erence to clinical symptoms. The consequencewas thatmany
SREs intherelevant trialswereofuncertainclinical significance.
This issuewas recently reviewedbySmithetal.18 Incontrast, in
ourTRAPEZEstudyandinsomeotherrecenttrials13 inCRPC,only
symptomatic SREs have been collected andmakes the clinical
andpotentially economic consequences aremuch clearer. The
USFoodandDrugAdministration (FDA)nowrefers to sympto-
maticSREsas symptomatic skeletal eventswhich isahelpfuland
relevantdistinction.Weshalluse this termfor the remainderof
the discussion. In the trial, ZA produced an increase in time to
first symptomatic skeletal event (Figure 2A), a substantial de-
crease in symptomatic skeletal events, as well as a decrease in
symptomaticskeletaleventsperpatient (Table2).Furthermore,
whenthedistributionof symptomatic skeletal eventsby type is
considered,thebiggesteffectofZAwasonthesymptomaticskel-
etal events thatmaybeconsidered themost severe (ie, fracture,
spinalcordcompression,andsurgerytobone)witha50%reduc-
tion, as compared with radiotherapy, which reduced sympto-
matic skeletal events by about one-third.
The prevention of serious events such as fracture, sur-
gery, and spinal cord compression (all associated with fre-
quent and prolonged admissions) is a high priority for clinical
services with great pressures on inpatient beds. Hence, a pre-
dictable outpatient therapy may be attractive to health care
providers if it prevents emergency, unpredictable resource-
intense visits. We did not carry out a patient preference study;
however, we believe it likely that patients would prefer a pre-
ventative treatment such as ZA to a reactive approach.
The main limitations to the data presented have been dis-
cussedherein. Inparticular, thedevelopmentofnewtreatments
for CRPCmakes Sr89 less relevantwith the advent of better ra-
dioisotopetherapyinradium-223.13ThelimitationsontheZAdata
aremore complex because the effects on symptomatic skeletal
eventsaresubstantial. It is likely that thesebenefitsarecomple-
mentary to those achievedwith other postdocetaxel therapies,
suchasabirateroneorenzalutamide. Inparticular, therearedata
that the benefit of radium-223 on symptomatic skeletal events
may be increased by ZA. Improved bone protecting agents that
preventhospitalvisitsmayalsoalterthepotentialbenefitsofthese
other agents.Althoughdenosumabwas superior toZA inCRPC
usingSREsorsymptomaticskeletaleventsasanendpoint, there
was no consensus on the use of one agent or the other in the St
Gallen 2015APCCCmeeting.17
Although commonly prescribed in the United States,
Canada, and several other countries, theuseof ZAandalsode-
nosumabremainscontroversial intheUnitedKingdomandelse-
where owing to doubts about the clinical relevance of the ra-
diological SREs in the licensing trials, particularly thequestion
ofwhetheradditionalboneprotection is relevant inpatients re-
ceiving life-prolonging CRPC therapy, such as chemotherapy
or new generation hormone therapies. The results of our trial
support theuseof ZA in the context of at least 1 life-prolonging
CRPC therapy (ie, docetaxel).
Conclusions
Strontium-89showedmodestbenefitsbutprobablyhasnowbeen
supersededwiththerecentlicenseforradium-223.Zoledronicacid
significantlyreducedseriousskeletalcomplicationsdefinedclini-
callyratherthanradiologicallyandshouldbeconsideredasacom-
ponent of therapy formenwith progressive bonyCRPC.
Table 2. Skeletal-Related Events by Category
SRE Type
Comparison, No.
ZA Sr89
No ZA ZA No Sr89 Sr89
Symptomatic pathological fracture 30 12 17 25
Spinal cord or nerve root compression 61 34 44 51
Cancer related surgery to bone 21 6 11 16
Hypercalcemia 2 0 0 2
Total most severe 114 52 72 94
Radiation 392 298 379 311
Change in antineoplastic therapy to treat bone pain 99 74 84 89
Total least severe 491 372 463 400
Overall total No. SREs 605 424 535 494
Abbreviations: SREs, skeletal-related
events; Sr89, strontium-89;
ZA, zoledronic acid.
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